Healthcare Companies Must Embrace New Funding Sources as Venture Investment Continues to Decline November 23, 2016

BIOPROCESSING - A New Era: Why the Time Has Come for Biopharma to Move to Continuous Bioprocessing January 13, 2020

Dr. Martin Smith explains why the pharma industry must embrace continuous processing if it’s to survive and thrive in an era of global personalized medicine.

DEVICE REGULATIONS - Early Preparation Will Pay Big Dividends as EU Enacts New EU Device Regulations January 8, 2018

Joanne Emmett says current directives are giving way to new regulations that require Class III and implantable devices to undergo clinical investigation to show that they are equal or superior to other products on the market.

CELL & GENE THERAPY - Cell & Gene Therapy’s Everest – The Challenges & Opportunities That Will Shape Success September 5, 2023

Samir Acharya, PhD, Rajiv Vaidya, PhD, Laura Kerepesi, PhD, and Cyrill Kellerhals, MBA, provide their unique insights as they explore the challenges cell and gene therapy developers and manufacturers are currently facing, those they can expect to see in the future, and more critically, how to overcome them.

SPECIAL FEATURE - Parenteral Drug Delivery: Could a Dose of AI Improve Development? May 1, 2023

Contributor Cindy H. Dubin speaks with several innovative companies to highlight the strides they are currently making toward improving dose accuracy, integrating design safety, and accelerating time to market.

SPECIAL FEATURE - Excipients: Exciting Expansion & Innovation April 4, 2022

Contributor Cindy H. Dubin speaks with several companies and presents a unique look at how excipients are being used to support current and future innovative active pharmaceutical ingredients.

EXECUTIVE INTERVIEW - inVibe: Changing the Research Game With Voice April 4, 2022

Fabio Gratton, CEO of inVibe, discusses patient-focused drug development (PFDD), his company’s language model, and the value this technology brings to a patient’s treatment journey.

INJECTABLES MANUFACTURING - Manufacturing Injectable Devices: Why Modern Means Modular May 3, 2021

Raffaele Pace, MMe, MBA, reviews how today’s drug delivery devices must be more mobile, less intrusive, and simpler than ever before – all while remaining cost competitive.

EXECUTIVE INTERVIEW - Pharmaceutics International, Inc: Getting Back to its Roots March 1, 2021

Sridhar Krishnan, Pii’s Senior Vice President, Operations and Strategic Initiatives, discusses how manufacturing is not solely where Pii wanted to be, so the company made a concerted effort to get back to its CDMO roots.

TURNAROUND CASE STUDY - A Pharma Industry Outsider’s Perspective - Turning Around the “ABCDMO” Company January 13, 2021

Paul Fioravanti, MBA, MPA, presents a case study on how he successfully turned around a failing CDMO that grew rapidly from one production location to eight in just 4 years, but was just few weeks away from running out of cash.

Cost of Disrupted Clinical Research Due to COVID-19 Equates to $10+ Billion & Potential Study Delays July 22, 2020

What if you developed a potential cure for COVID-19, but couldn’t test the drug because of COVID-19? Thousands of researchers worldwide are facing this dilemma, as clinical studies are interrupted, altered, postponed – or even cancelled…

DRUG DEVELOPMENT - To De-Risk Patient Acceptance of Biologic Drugs, Focus Early on Delivery September 11, 2017

Jeannie Joughin, PhD, asks what does a pharmaceutical company do when everyone wants more effective new therapies but no one – including third-party payers – wants to pay the price for their development? De-risk the drug development process, in every possible way.

INDUSTRY PERSPECTIVES - What Surprised You the Most This Past Year?: Your Colleague’s Perspectives June 30, 2016

The Global Formulation Report in this issue provided some interesting data on what has been happening in a number of key sectors over the past year. We thought it would be intriguing to hear what some of your colleagues said surprised them most.

ADVANCED DELIVERY DEVICES - Innovation Without Change: What is it & What Can it Mean for Pharmaceutical Manufacturers? January 7, 2015

John A. Merhige, MEM, and Dan Thayer believe a rigorous, risky development and regulatory process forces pharmaceutical manufacturers into a bad compromise between advances in delivery systems and the time, cost, and risk associated with those advances.

Delivering Value From Drug-Device Strategic Partnerships June 17, 2014

SPECIAL FEATURE - Outsourcing Formulation Development & Manufacturing: Early-Stage Partnerships Are On The Rise April 2, 2014

Contributor Cindy H. Dubin asked leading CMOs and CDMOs to describe the value-added services they offer with respect to formulation and manufacturing. Solving challenges of insufficient solubility, poor stability, identifying excipient candidates, and particle design topped their list of offerings.